11. Myasthenia
226 clinical trials,   172 drugs   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04101578 (ClinicalTrials.gov) | February 8, 2017 | 16/9/2019 | Clinical Prognosis and Progression of Myasthenia Gravis Patients | Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients | Myasthenia Gravis | Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) | Da, Yuwei, M.D. | NULL | Recruiting | 15 Years | N/A | All | 2000 | China | |
2 | JPRN-UMIN000015019 | 2014/09/02 | 02/09/2014 | Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG | Myasthenia gravis | Tacrolimus and IVIG | Kansai medical university | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not applicable | Japan | |
3 | NCT01179893 (ClinicalTrials.gov) | March 2007 | 9/8/2010 | Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis | A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis | Myasthenia Gravid | Biological: IVIG;Procedure: PLEX | University Health Network, Toronto | Grifols Therapeutics Inc. | Completed | 18 Years | N/A | Both | 87 | Phase 4 | Canada |
4 | NCT00306033 (ClinicalTrials.gov) | March 2004 | 21/3/2006 | Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis | IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial | Myasthenia Gravis | Drug: Intravenous ImmuneGlobulin | University Health Network, Toronto | NULL | Completed | 18 Years | N/A | Both | 50 | Phase 3 | Canada |